FDA slaps clin­i­cal hold on Ap­plied Ther­a­peu­tics af­ter sav­age fight over short at­tack

Ap­plied Ther­a­peu­tics has been hav­ing a rocky sum­mer.

Last month, an anony­mous short re­port ac­cused the small New York biotech of “cut­ting cor­ners” on its lead rare dis­ease pro­gram. Al­though the re­port made lit­tle dent on the stock, it in­censed the com­pa­ny enough that they threat­ened to pur­sue pros­e­cu­tion for “crim­i­nal ac­tiv­i­ty.”

On Mon­day, though, Ap­plied re­vealed that it’s not just some anony­mous crit­ic that has con­cerns about their pro­gram — so does the FDA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER